CD8A and type 1 diabetes mellitus: Clinical studies of anti-CD3 therapy in patients with recent-onset T1D showed that the therapy induces a population of regulatory/exhausted CD8 T cells in responders (6, 7), suggesting that anti-CD3 antibody therapy may also function to regulate T-cell exhaustion in addition to Treg.